Quarterly report [Sections 13 or 15(d)]

SEGMENT REPORTING - Significant expense categories (Details)

v3.25.3
SEGMENT REPORTING - Significant expense categories (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating Expenses:        
Loss from operations $ (11,750,432) $ (4,434,677) $ (29,395,189) $ (10,825,033)
Net Loss (Income): $ 11,580,126 $ (9,275,825) $ 29,045,059 $ (3,017,080)
Other segment items description Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense Other segment items included in segment loss include changes in warrant liability, interest income, and interest expense
Life science | Operating segment        
Operating Expenses:        
PMN310 development program costs $ 8,761,024 $ 1,914,804 $ 21,537,975 $ 4,537,978
Other non-employee research and development costs 214,128 205,722 712,712 624,694
Employee costs 1,520,464 1,020,095 4,016,789 2,137,126
Other general and administrative costs 1,254,816 1,294,056 3,127,713 3,525,235
Loss from operations 11,750,432 4,434,677 29,395,189 10,825,033
Other segment items (170,306) (13,710,502) (350,130) (13,842,113)
Net Loss (Income): $ 11,580,126 $ (9,275,825) $ 29,045,059 $ (3,017,080)